Table 4.

Characteristics of patients in AKI nonrecovered and recovered group during follow-up periods

VariablesAKI NonrecoveryAKI RecoveryP Value
N1916
Days from onset9 (7–14)7 (5–12)0.22a
Age64.0±8.164.5±14.70.89b
Sex (male)14/19 (73.7%)8/16 (50.0%)0.15c
Hypertension, %9/19 (47.4%)7/16 (43.8%)0.83c
Diabetes, %8/19 (42.1%)6/16 (37.5%)0.78bc
ACEI/ARB treatment history, %4/19 (21.1%)5/16 (31.3%)0.49c
Glucocorticoids treatment, %18/19 (94.7%)13/16 (81.3%)0.21c
Antibiotic treatment, %19/19 (100.0%)14/16 (87.5%)0.11c
Umifenovir treatment, %12/19 (63.2%)8/16 (50.0%)0.43c
Intravenous immunoglobulin therapy, %9/19 (47.4%)9/16 (56.3%)0.60c
Continuous KRT, %5/19 (26.3%)1/16 (6.3%)0.19d
Reexamined serum albumin, g/L25.9±5.931.3±5.90.01b
Reexamined lymphocytes, 109/L0.47 (0.32–0.85)0.93 (0.35–1.45)0.07a
Reexamined eosinophils, 109/L0.03 (0.00–0.13)0.04 (0.00–0.08)0.67a
SCR of baseline, μmol/L74.0 (61.0–89.0)72.5 (60.0–85.0)0.81a
COVID-19 grade<0.001a
 Moderate, %1/19 (5.3%)4/16 (25%)
 Severe, %0/19 (0.0%)6/16 (37.5%)
 Critically ill, %18/19 (94.7%)6/16 (37.5%)
Stage of AKI0.001a
 Stage 14/19 (21.1%)12/16 (75.0%)
 Stage 24/19 (21.1%)4/16 (25.0)
 Stage 311/19 (57.9%)0
Classification of AKI0.27d
 Prerenal AKI0/19 (0)2/16 (12.5%)
 Rhabdomyolysis-induced AKI3/19 (15.8%)1/16 (6.3%)
 Intrinsic AKI16/19 (84.2%)13/16 (81.3%)
Remission of proteinuria1/7 (14.3%)7/10 (70.0%)0.05d
Remission of hematuria1/7 (14.3%)2/6 (33.3%)0.56d
  • Data are presented as number and percentage, mean±SD, or median (25th–75th percentiles). SCR, serum creatinine.

  • a Wilcoxon rank-sum test.

  • b t test.

  • c Chi-square test.

  • d Fisher exact test.